
Science Resources RSS Feeds
|
 |
 |
 |
Bleeding during endoscopy: Do anti-inflammatories play a role?
March 16, 2007
MUHC researchers examine the evidence Does an aspirin-a-day increase the risk of bleeding during invasive diagnostic procedure? This is an important concern for many patients who take these and other antiplatelet agents in an effort to reduce heart attacks or strokes. Researchers at the MUHC have shown that antiplatelet drugs do not contribute to post-endoscopic bleeding. Their findings are published in this month's issue of Alimentary Pharmacology and Therapeutics.
"Clinical guidelines for use of antiplatelets during these procedures have been ambiguous," says Dr. Alan Barkun, MUHC Chief of Gastroenterology. "Some suggest withholding or stopping these medications ten days prior to the endoscopic procedure. Others will not perform the procedure if the patient was taking antiplatelet agents. In some cases this could have serious negative clinical implications. Our findings show that these precautionary measures are not necessary."
Barkun and his colleagues, including Nadeem Hussain, a clinician at the University of Western Ontario, compared the use of antiplatelets in patients who experienced bleeding with those who did not. Out of 126 endoscopy patients, they demonstrated that exposure to antiplatelets was not significantly associated with post procedure bleeding.
"Approximately 70 percent of individuals over the age of 65 are taking non steroidal anti-inflammatory medications or aspirin regularly. Our findings show that withholding these is not necessary for patients undergoing therapeutic endoscopic procedures," adds Dr. Barkun, a professor of medicine at McGill University. "This will also help ease any potential worry patients coming in for their screening colonoscopy exams may have. It is indeed important that individuals at risk for developing colorectal cancer come in for their procedures."
McGill University
|
 |

|
Handbook of Compounds with Anti-Inflammatory and Anti-Platelet Aggregation Activities Isolated from Plants
by Rosa Martha Perez Gutierrez (Author)
This book presents 848 compounds isolated and identified from plants that present anti-inflammatory and antiplatelet aggregation activities. These substances have been classified by chemical groups and each provides the most relevant information of its pharmacological activity, action mechanism, chemical structure, spectroscopic date, and other properties. Chemical structures have been drawn to indicate the stereochemistry. In this handbook the summary of the scientific information of plants that present biological activity and the compounds responsible for these activities is presented, which introduces the reader to the study of medicinal plants and also provides bibliographic references, where a detailed study of its chemistry and pharmacology can be found.
|

|
Bluebonnet Nutrition Policosanol 20 mg from sugar cane wax 60 Vegi Capsules
by Bluebonnet Nutrition
Policosanol is a natural supplement derived from sugar cane. It is a mixture of eight higher primary aliphatic alcohols isolated and purified from sugar cane wax. Cheap versions of policosanol that contain a high amount of octacosanol have flooded the American marketplace. If one expects to derive the benefits shown in the published studies, the other alcohols that make up the pharmaceutical approved policosanol product should be present.
Policosanol promotes healthy platelet function and helps to maintain cholesterol levels that are already within the normal range. Animal and human studies have also shown that policosanol is an antioxidant. When used in long-term clinical trials, policosanol was well tolerated and safe.
|

|
Preventing Ischemic Events: Advances in Antiplatelet Therapy (NCME Video 733)
Also With: Network For Continuing Medical Education (Primary Contributor), Alan T. Hirsch (Primary Contributor), Eric C. Ras (Primary Contributor), Eric J. Topol (Primary Contributor)
Atherosclerosis is a systemic disease that contributes to the death of 500,000 Americans by myocadial infarction and 150,000 Americans by stroke each year. In addition, peripheral arterial disease affects over 7 million Americans, two thirds of whom are undiagnosed. The modification of medical and lifestyle risk factors (e.g. diet, exercise, hypertension, smoking, and diabetes) and the daily administration of aspirin have been shown to save lives. However, aspirin is a relatively weak antiplatelet agent in that it interferes with one of the less significant intracellular processes that cause platelets to bind together. In this video, Drs. Hirsch, Raps, and Topol explore the role of new antiplatelet therapies in myocardial infarction, stroke, and peripheral arterial disease. Insights into...
|

|
Antiplatelet Therapy In Ischemic Heart Disease (American Heart Association Clinical Series)
by Stephen D. Wiviott (Author)
* Draws from expertise of leaders in antiplatelet therapy * Easy-to-use layout enables rapid browsing * Edited by a member of the prestigious TIMI study group with long-standing experience in the field
|
|
|
Triple therapy reduces primary stroke severity: the combination of antiplatelet therapy, statins, and ACE inhibitors also led to better outcomes.(Neurology): An article from: Internal Medicine News
by Damian McNamara (Author)
This digital document is an article from Internal Medicine News, published by Thomson Gale on July 1, 2005. The length of the article is 501 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Triple therapy reduces primary stroke severity: the combination of antiplatelet therapy, statins, and ACE inhibitors also led to better outcomes.(Neurology) Author: Damian McNamara Publication: Internal Medicine News (Magazine/Journal) Date: July 1, 2005 Publisher: Thomson Gale Volume: 38 Issue: 13 Page: 16(1)
Distributed by Thomson...
|

|
Anticoagulants, Antiplatelets, and Thrombolytics (Methods in Molecular Medicine)
by Shaker A. Mousa (Editor)
Albany College of Pharmacy, New York. Highlights the latest developments in antithrombotics and provides experimental methods for the discovery of new and improved anticoagulants. Presents relevant in vitro and in vivo models in thrombosis and hemostasis. For researchers and clinicians. DNLM: Anticoagulants--therapeutic use.
|

|
Antiplatelet Therapy in Atherothrombosis: Supplement Issue: Cerebrovascular Diseases 2006
by S. Uchiyama (Editor), T. Yamaguchi (Editor)
|
|
|
Guide to antithrombotic therapy: Anticoagulant and antiplatelet drugs
by James E Dalen (Author)
|
|
|
Metabolic syndrome blunts aspirin's antiplatelet activity.(CARDIOVASCULAR MEDICINE): An article from: Internal Medicine News
by Mitchel L. Zoler (Author)
This digital document is an article from Internal Medicine News, published by International Medical News Group on January 1, 2009. The length of the article is 333 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.
Citation Details Title: Metabolic syndrome blunts aspirin's antiplatelet activity.(CARDIOVASCULAR MEDICINE) Author: Mitchel L. Zoler Publication: Internal Medicine News (Magazine/Journal) Date: January 1, 2009 Publisher: International Medical News Group Volume: 42 Issue: 1 Page: 23(1)
Distributed by Gale, a part of Cengage...
|
|
|
Combo first to improve MI mortality in 12 years: dual antiplatelet therapy--aspirin plus a short course of clopidoxrel--shines in two large studies.(Cardiovascular ... An article from: Family Practice News
by Bruce Jancin (Author)
This digital document is an article from Family Practice News, published by International Medical News Group on April 15, 2005. The length of the article is 1296 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Combo first to improve MI mortality in 12 years: dual antiplatelet therapy--aspirin plus a short course of clopidoxrel--shines in two large studies.(Cardiovascular medicine)(Myocardial Infarction) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: April 15, 2005 Publisher: International Medical News Group Volume: 35 Issue: 8 ...
|
|